December 2012

Volume 53Issue 12p2487-2808
Open Access
COVER: Intracellular cholesterol homeostasis is modulated by the low density lipoprotein receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds the LDLR-LDL complex extracellularly, targeting the whole complex for degradation. Antibodies to PCSK9 may prevent the binding of PCSK9 to the LDLR-LDL complex, allowing increased recycling of the LDL receptor and increased LDL receptor numbers on the cell surface. This in turn results in increased catabolism of LDL particles, lowering plasma LDL cholesterol levels. (See Lambert et al., p. 2515.)...
COVER: Intracellular cholesterol homeostasis is modulated by the low density lipoprotein receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds the LDLR-LDL complex extracellularly, targeting the whole complex for degradation. Antibodies to PCSK9 may prevent the binding of PCSK9 to the LDLR-LDL complex, allowing increased recycling of the LDL receptor and increased LDL receptor numbers on the cell surface. This in turn results in increased catabolism of LDL particles, lowering plasma LDL cholesterol levels. (See Lambert et al., p. 2515.)

Commentary

Thematic Review Section: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases

Research Articles

Patient-Oriented and Epidemiological Research

Methods

Errata

Advertisement